Phase I Study: Monitoring Levodopa-Induced Dyskinesia Using Accelerometer & Gyroscope-based Motion Detection System

Great Lakes NeuroTechnologies Inc.1 site in 1 country15 target enrollmentAugust 2011

ConditionsParkinson's Disease Dyskinesia

Overview

Phase: N/A
Intervention: Not specified
Conditions: Parkinson's Disease
Sponsor: Great Lakes NeuroTechnologies Inc.
Enrollment: 15
Locations: 1
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to test whether body-worn wireless motion sensors can measure dyskinesias (involuntary movements caused by medications) in individuals with Parkinson disease (PD) independent of voluntary activity being performed and other PD motor symptoms (e.g. tremor).

Registry

clinicaltrials.gov

Start Date

August 2011

End Date

TBD

Last Updated

13 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Great Lakes NeuroTechnologies Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Clinical diagnosis of probable or definite idiopathic Parkinson Disease with motor fluctuations that include dyskinesias after taking their usual dose of levodopa/carbidopa

Exclusion Criteria

•Antipsychotic medications (including quetiapine and clozapine)
•Coexisting neurologic disease such as stroke or dementia
•Lacking capacity for informed consent
•Residing in a nursing home
•comorbid non-neurologic illnesses that impacts the ability to perform the study tasks
•Implantable defibrillators